# OnCo record nct07213674 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07213674/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07213674", "NCT07213674" ;
  schema:name "A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate "@en ;
  schema:description "A phase 3 trial of Xaluritamig, Abiraterone acetate, Docetaxel in prostate cancer, run by Amgen, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07213674/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07213674> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2025-11-28" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/> ;
  onco:drugs <https://onco.cc/drugs/xaluritamig/>, <https://onco.cc/drugs/abiraterone/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/drugs/cabazitaxel/> ;
  onco:companies <https://onco.cc/companies/amgen/> .